0000950170-24-038721.txt : 20240329
0000950170-24-038721.hdr.sgml : 20240329
20240329164639
ACCESSION NUMBER: 0000950170-24-038721
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240328
FILED AS OF DATE: 20240329
DATE AS OF CHANGE: 20240329
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller Deborah Ann
CENTRAL INDEX KEY: 0001868741
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40671
FILM NUMBER: 24804578
MAIL ADDRESS:
STREET 1: C/O NUVALENT, INC.
STREET 2: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nuvalent, Inc.
CENTRAL INDEX KEY: 0001861560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 508-446-2272
MAIL ADDRESS:
STREET 1: ONE BROADWAY, 14TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
ownership.xml
4
X0508
4
2024-03-28
0001861560
Nuvalent, Inc.
NUVL
0001868741
Miller Deborah Ann
C/O NUVALENT, INC.
ONE BROADWAY, 14TH FLOOR
CAMBRIDGE
MA
02142
false
true
false
false
Chief Legal Officer
true
Class A Common Stock
2024-03-28
4
M
false
13000
18.93
A
46300
D
Class A Common Stock
2024-03-28
4
M
false
9000
27.85
A
55300
D
Class A Common Stock
2024-03-28
4
S
false
2748
74.23
D
52552
D
Class A Common Stock
2024-03-28
4
S
false
16208
75.22
D
36344
D
Class A Common Stock
2024-03-28
4
S
false
3044
75.94
D
33300
D
Stock Option (Right to Buy)
18.93
2024-03-28
4
M
false
13000
0
D
2032-01-04
Class A Common Stock
13000
89000
D
Stock Option (Right to Buy)
27.85
2024-03-28
4
M
false
9000
0
D
2033-01-06
Class A Common Stock
9000
102154
D
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 27, 2023.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.76 to $74.74, inclusive. The reporting person undertakes to provide to the staff of the Securities and Exchange Commission, Nuvalent, Inc. or any security holder of Nuvalent, Inc., upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) of this Form 4.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.76 to $75.75, inclusive.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.76 to $76.13, inclusive.
The shares underlying this option vest as follows: 25% of the shares vested on January 4, 2023, and the remainder have vested or shall vest over the next three years thereafter in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
The shares underlying this option have vested or shall vest over the four years following January 6, 2023 in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.
/s/ Nathan McConarty, attorney-in-fact
2024-03-29